Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. The COVID-19 vaccine and treatment maker said Monday that it will pay $47.50 in cash for ...

Indiana's harvest nears completion, Pfizer acquires weight-loss drug company, YouTube TV issues refunds, and Starbucks struggles with cup demand.

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them

Pfizer reported a drop in third-quarter profits Tuesday as lower sales of Covid-19 products more than offset gains in other medications.

A Pfizer drug designed to address a severe problem associated with sickle cell disease failed to beat a placebo in a Phase 3 clinical trial. It’s the latest setback for Pfizer in this inherited blood disorder, coming nearly a year after the ...